You might find this situation amusing but like it or not DCVax-L works for GBM and would work as well or better for operable solid tumors anywhere in the body. Direct, which has been held back because DCVax-L broke down on the one lane highway to approval and blocked the road is even better because it works on all solid tumors, operable or not. Both are proven safe and by rights should have been made available for patients who are otherwise ‘dead anyway’ but ‘right to try’ is more like ‘right to die’ and seems to have done little to reduce bureaucratic hurdles for desperate patients. While shareholders have been losers here, and this is a stock forum, the patients are an issue.
So yes, I should have sold back in 2020 when mere hope of TLD was worth more than $2 a share. I would have plenty of time to rebuy my position between now and then. I guess I was not pessimistic enough. There is no point in holding the line when everyone else is withdrawing and leaving you to get eaten up by price declines. Still I am hard headed and hope that this time NWBO management will not pull the rug out from under us and will support any rally on MHRA approval unlike what happened in Fall 2020 or Spring 2022 (the former being indisputably their responsibility).
Market Data 
Markets 
AI
